COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,362 Articles (22,803 medRxiv, 8,559 bioRxiv)

Most recent first Previous |  Page 567: Articles 5661-5670  | Next

Increased insulin resistance due to Long COVID is associated with depressive symptoms and partly predicted by the inflammatory response during acute infection
Kadhem Al-Hakeim, H., Tahseen Al-Rubaye, H., S. Jubran, A., Almulla, A. F., Moustafa, S., Maes, M.
10.1101/2022.12.01.22283011 — Posted: 2022-12-04
Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the OpenSAFELY-UKRR linked platform and SRR database
The OpenSAFELY Collaborative, , Zheng, B., Campbell, J., Carr, E. J., Tazare, J., Nab, L., Mahalingasivam, V., Mehrkar, A., Santhakumaran, S., Steenkamp, R., Loud, F., Lyon, S., Scanlon, M., Hulme, W. J., Green, A. C., Curtis, H. J., Fisher, L., Parker, E., Goldacre, B., Douglas, I., Evans, S., MacKenna, B., Bell, S., Tomlinson, L., Nitsch, D., The LH&W NCS (or CONVALESCENCE) Collaborative
10.1101/2022.12.02.22283049 — Posted: 2022-12-04
Are fewer cases of diabetes mellitus diagnosed in the months after SARS-CoV-2 infection?
Reddy, N. V., Yeh, H.-C., Tronieri, J. S., Sturmer, T., Buse, J. B., Reusch, J. E., Johnson, S. G., Wong, R., Moffitt, R. A., Wilkins, K. J., Harper, J., Bramante, C. T.
10.1101/2022.12.02.22283029 — Posted: 2022-12-04
Durability of immune responses to the booster mRNA vaccination against COVID-19
S Arunachalam, P., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-y., Wali, B., Ellis, M., Huerta, C., Bechnack, K., Bechnack, S., Lee, M., Litvack, M., Losada, C., Grifoni, A., Sette, A., Zarnitsyna, V. I., Rouphael, N., Suthar, M. S., Pulendran, B.
10.1101/2022.12.02.22282921 — Posted: 2022-12-04
Evaluating primary and booster vaccination prioritization strategies for COVID-19 by age and high-contact employment status using data from contact surveys
Roubenoff, E. M., Feehan, D., Mahmud, A. M.
10.1101/2022.12.02.22283040 — Posted: 2022-12-04
The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as A Case Study
Di Fusco, M., Mendes, D., Steuten, L., Bloom, D. E., Drummond, M., Hauck, K., Pearson-Stuttard, J., Power, R., Salisbury, D., Towse, A., Roiz, J., Szabo, G., Yang, J., Marczell, K.
10.1101/2022.12.02.22283046 — Posted: 2022-12-04
Death, Inequality, and the Pandemic in the Nation's Capital
Alva, M., Illa, S. S., Haber, J. R.
10.1101/2022.12.02.22283039 — Posted: 2022-12-04
Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines
de Bruyn, G., Wang, J., Purvis, A., Sanchez Ruiz, M., Adhikarla, H., Alvi, S., Bonaparte, M. I., Brune, D., Bueso, A., Canter, R. M., Angeles Ceregido, M., Diemert, D., Finn, A., Forrat, R., Fu, B., Gallais, J., Griffin, P., Grillet, M.-H., Haney, O., Henderson, J. A., Koutsoukos, M., Launay, O., Martinon Torres, F., Masotti, R., Michael, N. L., Park, J., Rivera, D. M., Romanyak, N., Rook, C., Schuerman, L., Sher, L. D., Tavares-Da-Silva Sachin Deshmukh, F., Whittington, A., Chicz, R. M., Gurunathan, S., Savarino, S., Sridhar, S., VAT00002 booster cohorts study team
10.1101/2022.12.02.22282931 — Posted: 2022-12-03
Analysis of the ARTIC V4 and V4.1 SARS-CoV-2 primers and their impact on the detection of Omicron BA.1 and BA.2 lineage defining mutations
Ulhuq, F. R., Barge, M., Falconer, K., Wild, J., Fernandes, G., Gallagher, A., McGinley, S., Sugadol, A., Tariq, M., Maloney, D., Kenicer, J., Dewar, R., Templeton, K., McHugh, M.
10.1101/2022.12.01.22282842 — Posted: 2022-12-03
Evaluating the use of social contact data to produce age-specific forecasts of SARS-CoV-2 incidence
Munday, J. D., Abbott, S., Meakin, S., Funk, S.
10.1101/2022.12.02.22282935 — Posted: 2022-12-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).